MX2023002570A - Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer. - Google Patents

Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer.

Info

Publication number
MX2023002570A
MX2023002570A MX2023002570A MX2023002570A MX2023002570A MX 2023002570 A MX2023002570 A MX 2023002570A MX 2023002570 A MX2023002570 A MX 2023002570A MX 2023002570 A MX2023002570 A MX 2023002570A MX 2023002570 A MX2023002570 A MX 2023002570A
Authority
MX
Mexico
Prior art keywords
antagonist
cancer
vegfr
breast cancer
combination therapy
Prior art date
Application number
MX2023002570A
Other languages
English (en)
Inventor
Weon Sup Lee
Jin- San Yoo
Seon Young Lee
Sang Ryeol Shim
Original Assignee
Pharmabcine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmabcine Inc filed Critical Pharmabcine Inc
Publication of MX2023002570A publication Critical patent/MX2023002570A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

La presente descripción describe terapias de combinación que comprenden un antagonista de receptor de muerte celular programada 1 (PD-1) y un antagonista del receptor 2 del factor de crecimiento endotelial vascular (VEGFR-2), y el uso de las terapias de combinación para el tratamiento de un cáncer; en una modalidad, el cáncer es un glioblastoma, un cáncer de mama, un cáncer de mama triple negativo, un cáncer de mama metastásico, o un cáncer de mama triple negativo metastásico.
MX2023002570A 2020-09-02 2021-09-02 Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer. MX2023002570A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073512P 2020-09-02 2020-09-02
US202063122321P 2020-12-07 2020-12-07
PCT/IB2021/058043 WO2022049526A1 (en) 2020-09-02 2021-09-02 Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer

Publications (1)

Publication Number Publication Date
MX2023002570A true MX2023002570A (es) 2023-05-19

Family

ID=77914405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002570A MX2023002570A (es) 2020-09-02 2021-09-02 Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer.

Country Status (8)

Country Link
US (1) US20230265196A1 (es)
EP (1) EP4208482A1 (es)
JP (1) JP2023540490A (es)
KR (1) KR20230087451A (es)
AU (1) AU2021337223A1 (es)
CA (1) CA3189987A1 (es)
MX (1) MX2023002570A (es)
WO (1) WO2022049526A1 (es)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
MXPA01005515A (es) 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
EP2298346A3 (en) 2002-03-04 2011-11-16 Imclone LLC Human antibodies specific to kdr and uses thereof
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
EP2161336B2 (en) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
CN102131828B (zh) 2007-06-18 2015-06-17 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
EP2691112B1 (en) 2011-03-31 2018-05-23 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
TR201820873T4 (tr) 2011-08-01 2019-01-21 Hoffmann La Roche Pd-1 ekseni bağlayıcı antagonistler ve mek inhibitörlerinin kullanıldığı kanser tedavisine yönelik yöntemler.
EP3770176A1 (en) 2013-05-02 2021-01-27 AnaptysBio, Inc. Antibodies directed against programmed death-1 (pd-1)
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
PL3702373T3 (pl) 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3463456A1 (en) * 2016-06-03 2019-04-10 ImClone LLC Combination of ramucirumab and pembrolizumab for the treatment of certain cancers

Also Published As

Publication number Publication date
KR20230087451A (ko) 2023-06-16
WO2022049526A1 (en) 2022-03-10
US20230265196A1 (en) 2023-08-24
AU2021337223A1 (en) 2023-03-16
CA3189987A1 (en) 2022-03-10
EP4208482A1 (en) 2023-07-12
JP2023540490A (ja) 2023-09-25

Similar Documents

Publication Publication Date Title
Meng et al. Pericytes: a double-edged sword in cancer therapy
Singh et al. Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study
RU2008152435A (ru) Композиции и способы регулирования развития сосудов
WO2020176693A3 (en) Methods for treating map3k8 positive cancers
BR112022010806A2 (pt) Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama
MX2020008395A (es) Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas.
Russe et al. Autologous fat grafting for enhancement of breast reconstruction with a transverse myocutaneous gracilis flap: a cohort study
Vitzthum et al. Comparison of hematologic toxicity and bone marrow compensatory response in head and neck vs. cervical cancer patients undergoing chemoradiotherapy
Sayan et al. Hypofractionated postmastectomy radiation therapy
MX2023002570A (es) Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer.
Wobb et al. Comparison of chronic toxicities between brachytherapy-based accelerated partial breast irradiation and whole breast irradiation using intensity modulated radiotherapy
TW200610555A (en) Extended treatment of tumors through vessel occlusion with light activated drugs
MX2023003032A (es) Terapia de combinacion de un antagonista de pd-1 y un antagonista de lag3 y lenvatinib o una sal farmaceuticamente aceptable del mismo para el tratamiento de pacientes con cancer.
MX2022001450A (es) Metodo de tratamiento del cancer.
Maroun et al. Locally advanced cervical cancer in renal transplant patients: a dilemma between control and toxicity
Prado et al. Adyuvant fractionated radiotherapy after resection of intracranial hemangiopericytoma
Flynn Higher dose radiotherapy trial halves treatment time
Chargari et al. No evidence of increased skin toxicity with aromatase inhibitors and concurrent hypofractionated radiation therapy in menopausal breast cancer patients
Gangegowda et al. A new cannula for suction removal of parenchymal tissue of gynaecomastia
Vargo et al. Gynecologic Brachytherapy: Vaginal Cancer
Miri Hakimabad et al. EP-2145 Biological comparison of 60 Co & 192 Irbrachytherapy sources: a possible need for correction factor
Yathiraj et al. Randomized controlled trial to compare 3-dimensional conformal radiation therapy (3DCRT) to intensity modulated radiation therapy (IMRT) in head and neck squamous cell carcinoma
Starr Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations.
Hauge et al. PO-0984: Combined inhibition of Chk1 and Wee1 kinases for cancer treatment
CN105218647A (zh) Vegfr2阻断剂多肽及其应用